ARTICLE | Product Development

Quelling Qualms about Revlimid

Revlimid's survival data trumps secondary cancer risk in maintenance setting

May 16, 2011 7:00 AM UTC

Updated Phase III data on the use of Celgene Corp.'s Revlimid lenalidomide as maintenance therapy in multiple myeloma have quelled fears that the risk of second primary malignancies might outweigh the drug's survival benefit.

Questions about a possible association between Revlimid and second primary malignancies (SPMs) first cropped up at the American Society of Hematology meeting in December. The observations came from three ongoing Phase III trials in which higher rates of SPMs were seen in patients receiving Revlimid vs. those given placebo as maintenance therapy...